Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EP0062 in Relapsed Locally Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
NCT05573126Phase 2Recruiting
- Sponsor
- Ellipses Pharma
- Start
- Jan 2023
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of vosilasarm in breast cancer (4 arms), sponsored by Ellipses Pharma. Primary endpoints: Dose-Limiting Toxicities at 28 days, Maximum Tolerated Dose at 1 year and 2 more. Started Jan 2023; status: recruiting.
02
Drugs
vosilasarm
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05573126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05573126.